Fenofibrate plus Metformin Produces Cardioprotection in a Type 2 Diabetes and Acute Myocardial Infarction Model

Figure 4

Subchronic treatment with fenofibrate (F), metformin (M), and their combination reduced infarct size in control-ischemia/reperfusion (CTI/R) and diabetic-ischemia/reperfusion (DBI/R) conditions. (a) Representative photographs of Evans blue/triphenyltetrazolium chloride dyed heart slices from CTI/R and DBI/R rats, the blue area represents the area with viable tissue, the red area is the area at risk (AAR), and the white regions are the necrotic areas (NA). (b) Area at risk and (c) infarct size of the different groups, expressed as a percentage of AAR in the left ventricle and percentage of NA in the AAR, respectively. versus CTI/R-Vehicle and versus DBI/R-Vehicle two-way ANOVA followed by Duncan’s post hoc test. Data are presented as means ± SEM of 4–6 animals per group.

(a)

(b)

(c)